个性化医疗方法能否总体上，特别是在印度，对控制结核病有所贡献？
Can the personalized medicine approach contribute in controlling tuberculosis in general and India in particular?
作者信息
Khan Nikhat, Das Aparup
机构信息
ICMR-National Institute of Research in Tribal Health, NIRTH Campus, Jabalpur, Madhya Pradesh 482 003, India.
出版信息
Precis Clin Med. 2020 Jun 4;3(3):240-243. doi: 10.1093/pcmedi/pbaa021. eCollection 2020 Sep.
Abstract
Poor drug compliance and drug-resistant are the two principal obstacles in controlling tuberculosis (TB) in endemic regions including India, which has contributed the most to global TB burden. We argue here that a personalized medicine approach, to start with the -acetyl transferase-2-isoniazid (NAT2-INH) model, could be a step forward in dealing with both these limitations in controlling TB in India.
摘要
药物依从性差和耐药性是包括印度在内的结核病流行地区控制结核病的两大主要障碍，印度对全球结核病负担的贡献最大。我们在此认为，一种个性化医疗方法，首先从N-乙酰转移酶-2-异烟肼（NAT2-INH）模型入手，可能是在印度应对控制结核病的这两大限制方面向前迈出的一步。
相似文献
1
Can the personalized medicine approach contribute in controlling tuberculosis in general and India in particular?个性化医疗方法能否总体上，特别是在印度，对控制结核病有所贡献？
Precis Clin Med. 2020 Jun 4;3(3):240-243. doi: 10.1093/pcmedi/pbaa021. eCollection 2020 Sep.
2
Time for Isoniazid Pharmacogenomic-Guided Therapy of Tuberculosis Based on NAT2 Acetylation Profiles in India.基于印度 NAT2 乙酰化谱的异烟肼药物基因组导向结核病治疗时间。
Eur J Drug Metab Pharmacokinet. 2022 Jul;47(4):443-447. doi: 10.1007/s13318-022-00764-x. Epub 2022 Mar 28.
3
A case series of three patients presenting with isoniazid induced toxicity and N-acetyl transferase 2 gene mutation: A management conundrum for programmatic therapy of tuberculosis in India.三例异烟肼诱导毒性和 N-乙酰转移酶 2 基因突变患者的病例系列：印度结核病规划治疗的管理难题。
Indian J Tuberc. 2020 Jul;67(3):407-410. doi: 10.1016/j.ijtb.2020.01.005. Epub 2020 Jan 20.
4
A Systematic Review and Meta-analysis of Isoniazid Pharmacokinetics in Healthy Volunteers and Patients with Tuberculosis.异烟肼在健康志愿者和肺结核患者中的药代动力学的系统评价和荟萃分析。
Clin Ther. 2020 Nov;42(11):e220-e241. doi: 10.1016/j.clinthera.2020.09.009. Epub 2020 Oct 5.
5
Pharmacokinetics of thrice-weekly rifampicin, isoniazid and pyrazinamide in adult tuberculosis patients in India.印度成年结核病患者中每周三次利福平、异烟肼和吡嗪酰胺的药代动力学
Int J Tuberc Lung Dis. 2016 Sep;20(9):1236-41. doi: 10.5588/ijtld.16.0048.
6
Prognostic significance of novel mutations in tuberculosis.结核病新突变的预后意义
Int J Mycobacteriol. 2015 Mar;4(Suppl 1):51-52. doi: 10.1016/j.ijmyco.2014.11.043. Epub 2015 Jan 7.
7
The Role of -Acetyl Transferases on Isoniazid Resistance from and Human: An Approach.乙酰转移酶在结核分枝杆菌和人类异烟肼耐药性中的作用：一种体外研究方法。 （注：原文中“-Acetyl Transferases”表述不完整，推测可能是“N -Acetyl Transferases”等，这里按照常规理解补充完整并翻译，具体需结合完整准确的原文信息。）
Tuberc Respir Dis (Seoul). 2017 Jul;80(3):255-264. doi: 10.4046/trd.2017.80.3.255. Epub 2017 Jul 3.
8
The impact of isoniazid resistance on the treatment outcomes of smear positive re-treatment tuberculosis patients in the state of Andhra Pradesh, India.印度安得拉邦初治涂阳肺结核患者耐异烟肼对治疗结局的影响。
PLoS One. 2013 Oct 11;8(10):e76189. doi: 10.1371/journal.pone.0076189. eCollection 2013.
9
Prevalence of mutations in genes associated with isoniazid resistance in Mycobacterium tuberculosis isolates from re-treated smear-positive pulmonary tuberculosis patients: A meta-analysis.复治涂阳肺结核患者分枝杆菌分离株中与异烟肼耐药相关基因突变的流行率：一项荟萃分析。
J Glob Antimicrob Resist. 2018 Sep;14:253-259. doi: 10.1016/j.jgar.2018.02.009. Epub 2018 Mar 28.
10
Prevalence and factors associated with multidrug-resistant tuberculosis in South India.印度南部耐多药结核病的流行情况及相关因素。
Sci Rep. 2020 Oct 16;10(1):17552. doi: 10.1038/s41598-020-74432-y.
引用本文的文献
1
Effect of Genetic Variations in Drug-Metabolizing Enzymes and Drug Transporters on the Pharmacokinetics of Rifamycins: A Systematic Review.药物代谢酶和药物转运体基因变异对利福霉素类药物药代动力学的影响：一项系统评价
Pharmgenomics Pers Med. 2022 Jun 4;15:561-571. doi: 10.2147/PGPM.S363058. eCollection 2022.
本文引用的文献
1
Precision and personalized medicine and anti-TB treatment: Is TDM feasible for programmatic use?精准医学和个性化医学与抗结核治疗：TDM 用于规划用途是否可行？
Int J Infect Dis. 2020 Mar;92S:S5-S9. doi: 10.1016/j.ijid.2020.01.041. Epub 2020 Jan 26.
2
Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline.耐药结核病治疗。美国胸科学会/美国疾病控制与预防中心/欧洲呼吸学会/美国感染病学会临床实践指南。
Am J Respir Crit Care Med. 2019 Nov 15;200(10):e93-e142. doi: 10.1164/rccm.201909-1874ST.
3
Integrating Pharmacokinetics and Pharmacodynamics in Operational Research to End Tuberculosis.将药代动力学和药效学纳入运营研究以终结结核病。
Clin Infect Dis. 2020 Apr 10;70(8):1774-1780. doi: 10.1093/cid/ciz942.
4
Human Disease Variation in the Light of Population Genomics.人口基因组学视角下的人类疾病变异
Cell. 2019 Mar 21;177(1):115-131. doi: 10.1016/j.cell.2019.01.052.
5
Drug-resistant tuberculosis: is India ready for the challenge?耐多药结核病：印度是否准备好应对这一挑战？
BMJ Glob Health. 2018 Aug 10;3(4):e000971. doi: 10.1136/bmjgh-2018-000971. eCollection 2018.
6
Emergence of drug resistance in patients with tuberculosis cared for by the Indian health-care system: a dynamic modelling study.印度医疗体系中结核病患者的耐药性出现：一项动态建模研究。
Lancet Public Health. 2017 Jan;2(1):e47-e55. doi: 10.1016/S2468-2667(16)30035-4. Epub 2016 Dec 19.
7
Arylamine -acetyltransferase 2 genotype-dependent -acetylation of isoniazid in cryopreserved human hepatocytes.芳胺-N-乙酰基转移酶2基因型依赖性-异烟肼在冷冻保存的人肝细胞中的N-乙酰化作用
Acta Pharm Sin B. 2017 Jul;7(4):517-522. doi: 10.1016/j.apsb.2017.05.003. Epub 2017 Jun 7.
8
Isoniazid metabolism and hepatotoxicity.异烟肼代谢与肝毒性。
Acta Pharm Sin B. 2016 Sep;6(5):384-392. doi: 10.1016/j.apsb.2016.07.014. Epub 2016 Aug 3.
9
A Physiologically Based Pharmacokinetic Model of Isoniazid and Its Application in Individualizing Tuberculosis Chemotherapy.异烟肼的生理药代动力学模型及其在结核病个体化化疗中的应用
Antimicrob Agents Chemother. 2016 Sep 23;60(10):6134-45. doi: 10.1128/AAC.00508-16. Print 2016 Oct.
10
Personalized medicine for patients with MDR-TB.耐多药结核病患者的个体化医学。
J Antimicrob Chemother. 2016 Apr;71(4):852-5. doi: 10.1093/jac/dkv354. Epub 2015 Oct 27.
Zotero 插件